Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Total Current Assets

Last Annual Value

11.96M

3-Year CAGR

-6%

5-Year CAGR

32%

10-Year CAGR

15%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Total Current Assets

ANEB · NASDAQ
CompanyTotal Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
11.96M
2.1%-9.8%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
8.98M
-38.6%-30.3%N/A
101.24M
72.3%41.0%N/A
253.19M
-20.1%-6.3%N/A
80.24M
-8.0%-6.7%0.7%
58.05M
-31.3%-19.9%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
3.94M
48.1%30.4%N/A
87.58M
34.9%-1.9%N/A
133.27M
-6.4%6.9%15.6%
44.04M
-17.2%-17.0%N/A
52.11M
-20.1%-10.7%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72